DiaMedica Therapeutics upgraded by Oppenheimer with a new price target
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $7.00 | Buy | H.C. Wainwright |
| 4/24/2024 | $8.00 | Buy | Craig Hallum |
| 6/22/2023 | $7.00 | Perform → Outperform | Oppenheimer |
| 6/30/2021 | $38.00 → $32.00 | Buy | Roth Capital |